Terms: = Cervical cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
272 results:
1. Inclusion Complexes of
Pante GC; Castro JC; Lini RS; Romoli JCZ; Pires TY; Garcia FP; Nakamura CV; Mulati ACN; Matioli G; Machinski Junior M
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611905
[TBL] [Abstract] [Full Text] [Related]
2. Exploring genetic associations of Crohn's disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations.
Yu C; Xu J; Xu S; Tang L; Han Q; Zeng X; Huang Y; Yu T; Sun Z
Front Immunol; 2024; 15():1339207. PubMed ID: 38404590
[TBL] [Abstract] [Full Text] [Related]
3. MRI Plain Scan: A Tool in the Management of cervical cancer during Pregnancy.
Gao F; Qian T; Sun M; Lu Y; Cheng J; Fu L
Curr Med Imaging; 2024; 20():1-8. PubMed ID: 38389369
[TBL] [Abstract] [Full Text] [Related]
4. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic cervical cancer (COMPASSION-13): A Phase 2 Study.
Lou H; Cai H; Huang X; Li G; Wang L; Liu F; Qin W; Liu T; Liu W; Wang ZM; Li B; Xia Y; Wang J
Clin Cancer Res; 2024 Apr; 30(8):1501-1508. PubMed ID: 38372727
[TBL] [Abstract] [Full Text] [Related]
5. An engineered Accum-E7 protein-based vaccine with dual anti-cervical cancer activity.
Bikorimana JP; Abusarah J; Gonçalves M; Farah R; Saad W; Talbot S; Stanga D; Beaudoin S; Plouffe S; Rafei M
Cancer Sci; 2024 Apr; 115(4):1102-1113. PubMed ID: 38287511
[TBL] [Abstract] [Full Text] [Related]
6. An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for cervical cancer.
Lukovic J; Pintilie M; Han K; Fyles AW; Bruce JP; Quevedo R; Pugh TJ; Fjeldbo CS; Lyng H; Milosevic MF
Clin Cancer Res; 2024 Mar; 30(6):1200-1207. PubMed ID: 38180733
[TBL] [Abstract] [Full Text] [Related]
7. Fe(II) complexes of 2,2':6',2''-terpyridine ligands functionalized with substituted-phenyl groups: synthesis, crystal structures and anticancer potential.
Sun D; Huang X; Man R; Jia X; Song X; Wang S; Xue X; Liu H; Ma Z
Dalton Trans; 2023 Dec; 52(48):18416-18428. PubMed ID: 38009014
[TBL] [Abstract] [Full Text] [Related]
8. Safety and antitumour activity of cadonilimab, an anti-PD-1/ctla-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
[TBL] [Abstract] [Full Text] [Related]
9. Pathogenomics model for personalized medicine in cervical cancer: Cross-talk of gene expressions and pathological images related to oxidative stress.
Li J; Chen S; Wu J; Liu X; Liu H; Liu Y; Zhu Z
Environ Toxicol; 2024 Feb; 39(2):751-767. PubMed ID: 37755325
[TBL] [Abstract] [Full Text] [Related]
10. Characterization of tumor microenvironment and tumor immunology based on the double-stranded RNA-binding protein related genes in cervical cancer.
Li J; Wan C; Li X; Quan C; Li X; Wu X
J Transl Med; 2023 Sep; 21(1):647. PubMed ID: 37735483
[TBL] [Abstract] [Full Text] [Related]
11. Handheld vital microscopy for the identification of microcirculatory alterations in cervical intraepithelial neoplasia and cervical cancer.
Latul YP; Ince C; van Trommel NE; van den Brandhof-van den Berg A; Roovers JPWR; Kastelein AW
Microvasc Res; 2024 Jan; 151():104608. PubMed ID: 37690508
[TBL] [Abstract] [Full Text] [Related]
12. MLK4 as an immune marker and its correlation with immune infiltration in cervical squamous cell carcinoma and endocervical adenocarcinoma(CESC).
Gong M; Shen F; Li Y; Ming L; Hong L
PLoS One; 2023; 18(8):e0290462. PubMed ID: 37594950
[TBL] [Abstract] [Full Text] [Related]
13. The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge.
Li C; Cang W; Gu Y; Chen L; Xiang Y
Front Immunol; 2023; 14():1195476. PubMed ID: 37559727
[TBL] [Abstract] [Full Text] [Related]
14. Risk of uterine cervical cancer in inflammatory bowel disease: a systematic review and meta-analysis.
Kim J; Jung JH; Jo H; Kim MH; Kang DR; Kim HM
Scand J Gastroenterol; 2023; 58(12):1412-1421. PubMed ID: 37517000
[TBL] [Abstract] [Full Text] [Related]
15. Infection pattern and immunological characteristics of Epstein-Barr virus latent infection in cervical squamous cell carcinoma.
Zuo Y; Xiao H; Lv D; Huang M; Wang L; Liu J; Zhang K; Shen J; Wang Z; Wu Q; Xu Y
J Med Virol; 2023 Apr; 95(4):e28717. PubMed ID: 37184049
[TBL] [Abstract] [Full Text] [Related]
16. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/ctla4 dual blocker, in patients with advanced solid tumors.
Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
[TBL] [Abstract] [Full Text] [Related]
17. RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer.
Wang Y; Mao Y; Wang C; Jiang X; Tang Q; Wang L; Zhu J; Zhao M
Ann Med; 2023 Dec; 55(1):2190618. PubMed ID: 37042849
[TBL] [Abstract] [Full Text] [Related]
18. Signatures of immune cell infiltration for predicting immune escape and immunotherapy in cervical cancer.
Chen F; Shen L; Wang Y; Chen Y; Pan X; Liang H; Yu H
Aging (Albany NY); 2023 Mar; 15(5):1685-1698. PubMed ID: 36917087
[TBL] [Abstract] [Full Text] [Related]
19. Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study.
Miyata Y; Ogo E; Abe T; Hirata H; Tsuda N; Ushijima K; Kawahara A; Akiba J; Obara H; Kakuma T
Radiat Oncol; 2023 Feb; 18(1):40. PubMed ID: 36823665
[TBL] [Abstract] [Full Text] [Related]
20. Application of Immune Checkpoint Inhibitors in Gynecological cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract] [Full Text] [Related]
[Next]
